Cinacalcet
| File:Cinacalcet Structural Formulae.png | |
| Systematic (IUPAC) name | |
|---|---|
|
(R)-N-[-1-(1-naphthyl)ethyl]-3- [3-(trifluoromethyl)phenyl]propan-1-amine | |
| Clinical data | |
| [[Regulation of therapeutic goods |Template:Engvar data]] |
|
| Pregnancy category | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability |
20 to 25% Increases if taken with food |
| Protein binding | 93 to 97% |
| Metabolism | Hepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated) |
| Biological half-life | 30 to 40 hours |
| Excretion | Renal (80%) and fecal (15%) |
| Identifiers | |
| CAS Number | 226256-56-0 |
| ATC code | H05BX01 (WHO) |
| PubChem | CID 156419 |
| DrugBank | APRD00872 |
| Chemical data | |
| Formula | C22H22F3N |
| Molar mass | 357.412 g/mol[[Script error: No such module "String".]] |
| (verify) | |
Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of having end-stage renal disease.[1]. Cinacalcet is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.[2]
Clinical uses
Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and hypercalcemia in patients with parathyroid carcinoma.
Synthesis
B.C. Van Wagenen, S.T. Moe, M.F. Balandrin, E.G. DelMar, E.F. Nemeth, U.S. Patent 6,211,244 (2001).
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
- Sensipar website run by Amgen
- Prescribing information (package insert)
- Cinacalcet - Medlineplus.org
- Cinacalcet - Drug Digest.
- ↑ Torres PU (2006). "Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease". Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 16 (3): 253–8. doi:10.1053/j.jrn.2006.04.010. PMID 16825031.
- ↑ "Sensipar for Parathyroid Carcinoma". Amgen. 2009. Retrieved 25 September 2009.
